Aurobindo Pharma also clarified that the termination, effective December 27, 2025, was reached by mutual consent and is not expected to have any material impact on its broader biosimilars strategy.
Aurobindo Pharma also clarified that the termination, effective December 27, 2025, was reached by mutual consent and is not expected to have any material impact on its broader biosimilars strategy.